‘ECOG-ACRIN E2112 Participant Invitation’ of page ‘E2112 Participants Invitation’
Syndax Pharmaceuticals will be hosting a study dinner for ECOG-ACRIN study E2112, A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Men and Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer, on July 15, 2015 at the Crowne Plaza, in downtown Denver. A presentation on this Phase III trial including background on entinostat, […]
Read More